FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes: Table 1.
Authors: H. Lachmann, A. Simon, J. Anton, M. Gattorno, I. Kone-Paut, S. Ozen, J. Frenkel, E. Ben-Chetrit, H. Hoffman, A. Zeft, Y. Joubert, K. Lheritier, A. Speziale, G. Junge, J. Gregson, F. De Benedetti
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Periodic Fever Syndromes (PFS) are rare autoinflammatory conditions including Familial Mediterranean Fever (FMF), Hyper-IgD Syndrome/ Mevalonate Kinase Deficiency (HIDS/MKD), and TNF-Receptor Associated Periodic Syndrome (TRAPS).<sup>1</sup> It has been shown that colchicine-resistant FMF (crFMF), HIDS/MKD and TRAPS considerably impact physical and emotional aspects of patients9 lives.<sup>2–4</sup> Open label studies suggested that canakinumab (CAN), a fully human and highly specific anti-IL-1β monoclonal antibody, is efficacious in crFMF, HIDS/MKD and TRAPS.<sup>5–7</sup> To date, there is no data showing the effect of CAN on Health-Related Quality of Life (HRQoL) in PFS patients. <h3>Objectives</h3> To evaluate the effect of CAN on HRQoL using Child Health Questionnaire – Parent Form 50 (CHQ-PF50) and SF-12 Health Survey (SF-12) in PFS patients. <h3>Methods</h3> In a Phase 3 randomised placebo controlled study of CAN in PFS (NCT02059291), SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) were assessed in adults. For children (&gt;5–&lt;18 years), CHQ-PF50 Physical (PhS) and Psychosocial (PsS) Summary scores were assessed. <h3>Results</h3> 181 patients were randomised to CAN or placebo in 3 cohorts (63 crFMF, 72 MKD/HIDS, 46 TRAPS). 71 adults ≥18 years and 110 children (age range ≥2–&lt;18 years). Patients reported early clinically meaningful improvement in SF-12 PCS scores reported at Week (Wk) 5 which were sustained and increased to a large effect size by Wk 16 for all indications (Table). Similarly, clinically meaningful improvements in SF-12 MCS, CHQ-PF50 PhS and PsS was observed in all indications, with the exception of PsS in HIDS/MKD and TRAPS patients (Table). <h3>Conclusions</h3> Canakinumab showed rapid improvement by Week 5 in patient reported outcomes in adults and children with PFS, which was sustained through Week 16. <h3>References</h3> Savic S. and Wood P. Clin. Med. 2011;11(4):396–401 Dandekar P, et al. Pediatr. Rheumatol. 13(S1):P22 Dandekar P, et al. Pediatr. Rheumatol. 13(S1):P23 Dandekar P, et al. Pediatr. Rheumatol. 13(S1):P24 Brik R, et al. Arthritis Rheumatol. 2014;66(11):3241–3 Arostegui, J.I, et al. Arthritis Rheumatol. 2015; 67 (S10) Gattorno M, et al. Arthritis Rheumatol. 2015; 67 (S10) User9s manual for the SF-12v2 Health Survey, 3rd ed. 2012 Cohen J, et. al. Statistical Power Analysis for the Behavioural Sciences,2nd ed. 1988 <h3>Disclosure of Interest</h3> H. Lachmann Consultant for: Novartis, SOBI, Takeda, GSK, Speakers bureau: Novartis, SOBI, A. Simon Grant/research support from: CSL Behring, Novartis, Xoma/Servier, J. Anton Grant/research support from: Novartis, Pfizer, Abbvie, Roche, SOBI, Consultant for: Novartis, M. Gattorno Grant/research support from: Novartis, SOBI, Consultant for: Novartis, SOBI, Speakers bureau: Novartis, SOBI, I. Kone-Paut Grant/research support from: SOBI, Roche, Novartis, Consultant for: Novartis, SOBI, Pfizer, Abbvie, Chugai, S. Ozen Consultant for: Novartis, Speakers bureau: SOBI, J. Frenkel Grant/research support from: Novartis, SOBI, E. Ben-Chetrit Consultant for: Novartis, H. Hoffman Grant/research support from: Bristol Myers Squibb, Consultant for: Novartis, Sob Biovitrum, Regeneron, Speakers bureau: Novartis, A. Zeft: None declared, Y. Joubert Employee of: Novartis, K. Lheritier Employee of: Novartis, A. Speziale: None declared, G. Junge Employee of: Novartis, J. Gregson Employee of: Novartis, F. De Benedetti Grant/research support from: Pfizer, Abbvie, Roche, Novartis, Novimmune, BMS